Can DES Supplier Strategy, R&D Investments Rival Pharma? Tobin Thinks So

Boston Scientific's early decision to manufacture the Taxus paclitaxel-eluting stent in excess of market demand allowed the firm to restore U.S. inventory levels within 48 hours of the firm's July 16 recall, according to Chairman & CEO Jim Tobin